Search clinical trials for: Anti-DNA Antibody

Total 5190 results

Institute of Hematology & Blood Diseases Hospital

Recruiting

An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A (AHA2023)

Acquired Hemophilia

China
Beijing Friendship Hospital

Recruiting

Prospective Study of Immune Function and PD-1 Antibody Therapy Efficacy Predictors on CAEBV and EBV-HLH Patients

Chronic Active Epstein-Barr Virus Infection | Secondary Hemophagocytic Lymphohistiocytosis

China
Kirby Institute

Recruiting

Australian Hepatitis and Risk Survey in Prisons (AusHep)

HIV Infections | Hepatitis B | Hepatitis C

Australia
CrystalGenomics, Inc.

Recruiting

Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Non Squamous Non Small Cell Lung Cancer

Korea, Republic of
AstraZeneca

Recruiting

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants (SLE)

Systemic Lupus Erythematosus

China, Italy, United States, Portugal, Spain, Turkey, Mexico, United Kingdom, Colombia, France, Germany, Brazil, Canada, Argentina, Poland, South Africa
Changchun BCHT Biotechnology Co.
The First Affiliated Hospital of Yunnan University of Traditional Chinese... and other collaborators

Not yet recruiting

Safety, Pharmacokinetics, and Pharmacodynamic Testing of Rabies mAb CBB 1

Rabies Virus Infection

China
MedMira Laboratories Inc.
Public Health Agency of Canada (PHAC)

Recruiting

Evaluation of the Sensitivity, Specificity, and Utility of the Reveal® TP (Syphilis) Antibody POCT

Syphilis | Syphilis Infection | Early Syphilis, Symptomatic

Canada
Zhejiang University
Zcapsule Pharmaceuticals (Shaoxing) Co., Ltd

Recruiting

The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1

Ovarian Cancer | Bladder Cancer | Small-cell Lung Cancer | Liver Cancer | Esophagus Cancer

China
Chang Gung Memorial Hospital

Recruiting

Association of Phenotypic Age and Antibody Titers Among SARS-Co-V2 Infected Patients and Vaccinated Groups

COVID-19

Taiwan
Sun Yat-sen University

Not yet recruiting

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

Cervical Cancer | Cervical Carcinoma

China
Sun Yat-sen University

Not yet recruiting

Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer

Endometrial Cancer | Endometrial Adenocarcinoma

China
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Investigation of the Passage of Antiviral Antibodies From Mother to Child (TransAc)

Pregnant Woman | Adult Patient
Institut Claudius Regaud
AstraZeneca; National Cancer Institute, France

Recruiting

Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic Sarcoma (MEDISARC-SBRT)

Soft Tissue Sarcoma

France
Ou Bai, MD/PHD
Second Hospital of Jilin University; China-Japan Union Hospital, Jilin University

Recruiting

Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.

Angioimmunoblastic T-cell Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise Specified

China
Centre Hospitalier Universitaire de Nīmes

Recruiting

Optimizing Anti-IL17 Antibody Therapy by Associating Fiber Supplementation to Correct Treatment-aggravated Gut Dysbiosis in Axial Spondyloarthritis - RESPOND-IL17 (RESPOND-IL17)

Axial Spondyloarthritis

France
Christoph Königs
Roche Pharma AG; Chugai Pharma Germany GmbH

Recruiting

Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab (NAVIGATE)

Severe Hemophilia A | Severe Hemophilia A With Inhibitor | Severe Hemophilia A Without Inhibitor

Germany
Shanghai HyaMab Biotech Co.,Ltd.

Recruiting

PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor

Locally Advanced/Metastatic Solid Tumors

China
Beijing Tongren Hospital
Hainan Linheng Pharmaceutical Co., Ltd.

Recruiting

Bioequivalence Study of Calcium Hydroxybenzene Sulphonate Dispersible Tablets in Chinese Healthy Volunteers

Bioequivalence Study

China
Shenzhen People's Hospital
Sixth Affiliated Hospital, Sun Yat-sen University; The University of Hong Kong-Shenzhen...

Recruiting

Neoadjuvant Cadonilimab Plus Chemotherapy Following Short-Course Radiotherapy in Locally Advanced Rectal Cancer (NeoCaCRT)

Locally Advanced Rectal Carcinoma

China
Second Affiliated Hospital of Soochow University
SciClone Pharmaceuticals

Recruiting

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Advanced Solid Tumor | Refractory Tumor

China
Neuramedy Co. Ltd.
Quotient Sciences

Not yet recruiting

Single and Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of NM-101

Parkinson Disease

United Kingdom
Cairo University

Not yet recruiting

Microneedling With Vitamin C Versus Injectable Vitamin C for Depigmentation in Gingival Melanin Hyperpigmentation

Gingival Pigmentation
Shanghai Henlius Biotech

Not yet recruiting

Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX51 in Patients With Solid Tumor or Lymphoma

Solid Tumor, Adult Lymphoma
Shanghai Henlius Biotech

Recruiting

A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients

NSCLC Stage IV

China
IRCCS San Raffaele

Recruiting

Patients Pregnant Women With or Without Primary Antiphospholipid Antibody Syndrome

Rheumatic Diseases | Pregnancy Complications | Pregnancy, High Risk | Preeclampsia | Immunologic Disease | Antiphospholipid Antibody Syndrome Primary

Italy
Timothy Voorhees

Recruiting

Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder

Polymorphic Post-Transplant Lymphoproliferative Disorder | Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder

United States
University Hospital, Grenoble

Not yet recruiting

Immune Response in Desensitized Patients (DELIGHT)

Kidney Transplant Rejection
Hospital Clínico Universitario de Valladolid
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León

Recruiting

Anti-CGRP Monoclonal Antibody Response After Switching (AMARAS) (AMARAS)

Migraine | Head Pain

Spain
First Affiliated Hospital, Sun Yat-Sen University
Nanfang Hospital of Southern Medical University; Sun Yat-Sen Memorial Hospital... and other collaborators

Not yet recruiting

BAFF/APRIL in Kidney Transplant Rejection Risk Assessment (BA-TRAP)

Kidney Transplantation | Kidney Transplant Rejection

China
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Shandong Cancer Hospital and Institute

Recruiting

IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors

Breast Cancer | Small Cell Lung Cancer | Colorectal Cancer | Advanced Solid Tumor | Non-small Cell Lung Cancer | Squamous Cell Cancer of Head and Neck

China
National Cancer Institute (NCI)

Recruiting

Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer

United States
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Postoperative Management for HNSCC Based on Pathological Response of Induction Chemotherapy and Immunotherapy (HN)

Head and Neck Cancer

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Comparing of the PK, PD, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults

Healthy

China
Beijing Friendship Hospital

Not yet recruiting

L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH

Lymphoma | Hemophagocytic Lymphohistiocytosis | PD-1 Antibody | Epstein-Barr Virus

China
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC; Seagen Inc.

Not yet recruiting

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

Renal Pelvis and Ureter Urothelial Carcinoma

United States
AstraZeneca

Recruiting

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Hepatocellular Carcinoma | Biliary Tract Cancer

China, Spain, Korea, Republic of, Italy, United Kingdom, United States, Japan, Taiwan, Hong Kong
Fudan University

Recruiting

The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma (RAPID)

High-Risk Localized Soft Tissue Sarcoma

China
The Second Affiliated Hospital of Chongqing Medical...
Guizhou Provincial People's Hospital; The Affiliated Hospital Of Southwest...

Not yet recruiting

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)

Chronic Hepatitis b | Anti-PD-1 Antibody | Peg-IFNα

China
The Second Affiliated Hospital of Chongqing Medical...
Guizhou Provincial People's Hospital; The Affiliated Hospital Of Southwest...

Not yet recruiting

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A)

Chronic Hepatitis b | Anti-PD-1 Antibody

China
Bio-Thera Solutions
Sun Yat-sen University

Recruiting

BAT7104 Injection in Patients With Advanced Malignant Tumors.

Advanced Malignant Tumor

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors (IUNU-RC)

Non-clear Renal Cell Carcinoma

China
Novartis Pharmaceuticals

Recruiting

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) (REPLENISH)

Polymyalgia Rheumatica

United States, Australia, Germany, Belgium, France, Spain, Italy, Lebanon, Switzerland, Japan, Israel, Denmark, Argentina, Netherlands, Colombia, Chile, Hungary, Poland, Turkey, Czechia, Brazil, South Africa, Mexico, Canada, United Kingdom
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Locally Advanced

China
ImmunOs Therapeutics AG
Merck Sharp & Dohme LLC

Recruiting

A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors

Solid Tumor, Adult

Australia
Sinocelltech Ltd.

Not yet recruiting

Study on the Antibody Level Against SARS-CoV-2 （COVID-19）in Dazhu County in 2023 (COVID-19)

COVID-19

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer

Advanced or Metastatic Urothelium Cancer

China
Emory University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Astellas Pharma Inc; Seagen...

Recruiting

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Stage III Bladder Cancer AJCC v8 | Stage IV Bladder Cancer AJCC v8 | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Metastatic Bladder Carcinoma | Urachal Adenocarcinoma | Locally Advanced Bladder Carcinoma | Malignant Renal Pelvis Neoplasm | Malignant Ureter Neoplasm | Malignant Urethral Neoplasm and other conditions

United States
Shanghai Fosun Pharmaceutical Industrial Development...

Recruiting

FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Breast Cancer

China
Shanghai Miracogen Inc.

Not yet recruiting

A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN

Squamous Cell Carcinoma of the Head and Neck

China
OSE Immunotherapeutics

Recruiting

Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas

Lymphoma | Solid Advanced Tumor

France, Belgium

Search clinical trials for: Anti-DNA Antibody

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations